Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults With Early Rheumatoid Arthritis Who Are Methotrexate Naive

Next Previous
Search
Trial Profile

A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults With Early Rheumatoid Arthritis Who Are Methotrexate Naive

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms AVERT-2
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 15 Jun 2024 Results (n=746) assessing the association of baseline (BL) circulated biomarkers with disease activity (DA) measures and their ability to predict clinical response in MTX-naive, ACPA+ patients with early RA presented at the 25th Annual Congress of the European League Against Rheumatism
    • 15 Nov 2023 Results evaluating the association of baseline circulated biomarkers with disease activity measures and their ability to predict clinical response in patients with early rheumatoid arthritis presented at the ACR Convergence 2023.
    • 22 Apr 2023 Primary endpoint (Percentage of Participants in Simple Disease Activity Index (SDAI) Remission at Week 24) has not been met, as per results published in the Arthritis Research and Therapy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top